News

CR Bard has reported an increase in net income by 44% to $112.2 million and diluted earnings per share of $1.11, an increase of 46%, for the second

OSI Pharmaceuticals has reported total revenues from continuing operations of $99 million for the second quarter of 2009, as compared to revenues of $96 million for the second

Celera has reported preliminary revenue results for the quarter ended June 27, 2009. The company expects to garner revenue for the second quarter of 2009 in the range

STAAR Surgical has been informed by the FDA Division of Bioresearch Monitoring that the restrictions of the integrity hold put in place by the FDA on August 3,

Medfusion has acquired Medem’s iHealth suite of services for physicians and the iHealth Personal Health Record solution for patients. Medfusion provides solutions for both practice and patient, and

FoldRx has reported positive results from its pivotal phase II/III clinical study of ttafamidis (Fx-1006A), in patients suffering from TTR amyloid polyneuropathy (ATTR-PN). Its a fatal orphan disease

Idaho Technology is a privately held biotechnology company based in Salt Lake City, Utah.

Gilead has posted a total revenue of $1.65 billion for the second quarter of 2009, an increase of 29% compared to total revenues of $1.28 billion for the

Pfizer has posted a Q2 revenues of $11.0 billion, which is a decrease of 9% compared with the year-ago quarter. For second-quarter 2009, US revenues were $4.5 billion,